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CASE REPORT
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with chemotherapy and ALK inhibitor-resistant 
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Abstract 
Background: The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase, which was first identi-
fied as the fusion partner of the nucleophosmin (NPM1) gene in the recurrent t(2;5)(p23;q35) found in a subset of 
anaplastic large cell lymphoma (ALCL). Several distinct, non-NPM1, ALK fusions have subsequently been described in 
lymphomas and other tumor types. All of these fusions result in the constitutive expression and activation of ALK and 
ALK signaling pathways, ultimately leading to the malignant phenotype.
Case report: A non-NPM1 fusion partner of ALK was identified in a 32-year-old Caucasian male ALCL patient whose 
disease was refractory to standard chemotherapy and autologous stem cell transplantation, and exhibited a poor 
response to a first-generation ALK inhibitor. Non-allele-specific ALK RT-qPCR revealed ALK overexpression and 5′ RACE 
PCR revealed that the patient’s lymphoma expressed a TRAF1-ALK fusion.
Conclusions: We report the case of an ALCL patient whose tumor harbored the newly recognized TRAF1-ALK fusion 
and describe the clinical outcome after treatment with an ALK inhibitor. The short survival of our patient may reflect a 
propensity toward aggressive behavior in lymphomas that express this ALK fusion.
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Background
The anaplastic lymphoma kinase (ALK) gene was discov-
ered in 1994 as the fusion partner of the nucleophosmin 
(NPM1) gene in the recurrent t(2;5) chromosomal trans-
location in anaplastic large-cell lymphoma (ALCL) [1]. 
The NPM1-ALK fusion protein produced by this rear-
rangement results in constitutive activation of the ALK 
kinase and is associated with the deregulation of multiple 
signaling pathways downstream of ALK, culminating in 
increased cellular proliferation, survival and migration 
[2]. Since the original description of the NPM1-ALK 
fusion gene in ALCL, a large number of distinct ALK 
fusion partners have been identified in ALCL as well as 
a variety of other malignancies including diffuse large B 
cell lymphoma, inflammatory myofibroblastic tumor, 
non-small cell lung cancer, and renal cell carcinoma [2, 
3]. Patients with ALK-positive ALCL treated with ALK 
inhibitors typically have high response rates and durable 
progression-free survivals, even if they have been heavily 
pretreated [4, 5].
Recently, a novel fusion was described between the 
TNF receptor-associated factor 1 (TRAF1) gene and ALK 
in an ALCL patient who experienced an almost 3-dec-
ade history characterized by several disease relapses fol-
lowed ultimately by apparently successful treatment with 
high-dose chemotherapy and autologous stem cell trans-
plantation [6]. In this report we describe an additional 
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ALCL patient whose tumor contained a TRAF1-ALK 
fusion. Unlike the case described by Feldman et  al. [6], 
our patient had aggressive disease characterized by poor 
responses to chemotherapy, autologous transplantation, 
a CD30 antibody–drug conjugate, and a first-generation 
ALK tyrosine kinase inhibitor.
Case report
The patient was a 32-year-old Caucasian male who was 
diagnosed in 2004 with mycosis fungoides after develop-
ing a pruritic rash. There was no family history of can-
cer. He was initially treated with topical nitrogen mustard 
and later received UVB narrow band therapy. In October 
2012, the patient presented with a cough, dyspnea, fever, 
chills, left pleuritic chest pain and significant weight loss. 
These symptoms were associated with a flare of his skin 
lesions. A CT scan of the chest demonstrated extensive 
left cervical, supraclavicular and mediastinal adenopa-
thy, as well as left upper lobe airspace disease. Review of 
pathology from a left cervical lymph node biopsy from 
December 2012 revealed complete effacement of the nor-
mal architecture by a diffuse infiltration of large and giant 
pleomorphic lymphocytes characterized by conspicu-
ous nucleoli and large amounts of cytoplasm (Figure 1a). 
Immunohistochemical stains showed weak CD45 and 
strong CD43 expression (Figure  1b), with strong CD30 
expression in the membrane and Golgi patterns (Fig-
ure 1c). The malignant cells expressed cytoplasmic ALK 
(Figure 1d) but lacked expression of CD 3, 4, 5 and 8. A 
T cell lineage was confirmed in the tumor cells of the ini-
tial biopsy sample by clonal T-cell receptor gamma gene 
rearrangement. Identical infiltrates were identified in 
material from recurrent biopsies of skin and subcutane-
ous tissue, and from lung and endobronchial biopsies at 
the time of progression.
After an initial response to four cycles of cyclophos-
phamide, doxorubicin, vincristine and prednisone 
(CHOP) chemotherapy, the disease progressed rapidly 
Figure 1 Pathologic findings in the lymph node biopsy. a Diffuse infiltration of large and pleomorphic lymphocytes (H&E, ×600). b Membranous 
expression of CD43 (×600). c Membranous and golgi expression of CD30 (×600). d Cytoplasmic expression of ALK (×600).
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while the patient was on therapy. He was started on 
gemcitabine, dexamethasone and cisplatin (GDP) 
chemotherapy in preparation for an autologous stem 
cell transplant but progressed after 3 cycles. The 
patient then received one cycle of the CD30 antibody–
drug conjugate brentuximab, with a response but toler-
ated the treatment poorly. He was subsequently started 
on the ALK small-molecule kinase inhibitor crizotinib 
and tolerated the therapy well with an improved per-
formance status. A fluoro-deoxyglucose positron emis-
sion tomography (FDG-PET) scan performed after 
3 months of crizotinib showed an improvement in the 
previously noted airspace disease in the left lung but 
an enlarging FDG-avid 5.2 cm mass in the apex of the 
left lung. There was no evidence of disease outside 
the chest. A CT scan-guided biopsy of this mass was 
positive for ALK by immunohistochemistry and RT-
qPCR using an ALK RGQ RT-PCR Kit (Qiagen, Hilden, 
Germany). The remaining RNA from the lymph node 
biopsy was reverse transcribed to cDNA and used in a 
5′ RACE PCR followed by Sanger sequencing to iden-
tify the ALK fusion partner. Analysis of sequence data 
revealed a TRAF1-ALK fusion in which 3′ end of exon 
6 of TRAF1 was fused to the 5′ end of exon 20 of ALK 
(Figure  2). The mRNA fusion junction in TRAF1 and 
ALK in the case was identical to that present in the 
TRAF1-ALK-positive ALCL case reported by Feldman 
et al. [6].
The patient underwent an unrelated-donor stem cell 
transplant in December 2013 but disease recurred in the 
left lung within 3  months post-transplant, and failed to 
respond to the reintroduction of crizotinib and bren-
tuximab. Endobronchial biopsies from lesions in the left 
and right lungs revealed ALK-positive ALCL. The patient 
died of progressive lymphoma 6 months post-transplant.
Molecular testing of the patient’s biopsy samples was 
performed with the consent of the patient using a study 
assay approved by the BC Cancer Agency Research Eth-
ics Board (H13-01763) and conducted in accordance with 
the ethical principles of the Declaration of Helsinki.
Conclusions
We describe an additional case of TRAF1-ALK fusion 
in ALCL. Unlike the initial case, which was character-
ized by a nearly 3-decade course punctuated by multiple 
therapy-responsive relapses [6], our patient had a short 
survival after responding poorly to chemotherapy, autol-
ogous stem cell transplantation, CD30 antibody–drug 
conjugate therapy, and the first-generation ALK inhibitor 
crizotinib.
Of note, while this case report was undergoing peer 
review an independent study of two additional cases 
of TRAF1-ALK-expressing ALCL was published [7]. 
Interestingly, these two cases had very different clini-
cal courses: one was a chemotherapy refractory patient 
whose tumor rapidly progressed to a leukemic phase 
and contained additional genetic abnormalities (TP53 
loss, cMYC amplification, PRDM1/Blimp1 loss) that may 
have contributed to the aggressiveness of the malignancy 
while the second was an 11-year-old whose ALCL lacked 
these genetic abnormalities and who had a remarkable 
anti-tumor response to conventional chemotherapy and 
remains in clinical remission. This study also presented 
experimental data suggesting that the activation of NFκB 
signaling—mediated by the interaction of TRAF1-ALK 
with TRAF2, which in turn modulates CD30-mediated 
activation of NFκB—contributes to oncogenesis associ-
ated with TRAF1-ALK [7].
Whether the natural histories observed for these cases 
are related at least in part to the presence of TRAF1-
ALK rather than the more common NPM1-ALK fusion 
is unclear given the limited clinical experience with 
TRAF1-ALK-positive ALCL. Preclinical analysis has sug-
gested that various ALK fusions that differ only in the 
identity of their partner genes respond with differential 
sensitivity to structurally diverse ALK kinase inhibitors 
[8]. However, it is not yet clear if these preclinical differ-
ences are of clinical relevance.
Nevertheless, some NPM1-ALK-positive ALCL 
patients who have progressed after multiple prior thera-
pies have been shown to respond favorably to crizotinib 
Figure 2 Sanger sequencing electropherogram of the TRAF1 exon 6-ALK exon 20 fusion junction. The sequences in blue are from exon 6 of the 
TRAF1 gene. The sequences in red are from exon 20 of ALK. The TRAF1-ALK fusion junction in this case is identical to that previously reported in the 
literature by Feldman and colleagues [6] and Abate et al. [7].
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[4, 5]. ALK-inhibitor resistance-causing mutations have 
been detected in NPM1-ALK-positive ALCL patients 
who have not responded to ALK inhibitors [4]. Interest-
ingly, some of the NPM1-ALK-positive ALCL patients 
who failed to respond to crizotinib have been shown to 
harbor inhibitor resistance mutations after only brief 
(1–2 month) treatment with the kinase inhibitor, suggest-
ing the presence of the mutations de novo (i.e., prior to 
inhibitor therapy) [4]. Our patient may have had one or 
more primary resistance-causing mutations at diagno-
sis or developed ALK inhibitor resistance after multiple 
lines of cytotoxic chemotherapy. In addition, however, 
the patient’s failure to achieve a sustained response to 
cytotoxic therapy, a CD30 antibody–drug conjugate or 
an ALK inhibitor suggests the presence of one or more 
alternative drug resistance mechanisms in addition to the 
possible presence of ALK inhibitor resistance mutations.
Consent
Written informed consent was obtained from the 
patient’s next-of-kin (mother) for publication of this Case 
report and any accompanying images. A copy of the writ-
ten consent is available for review from the Editor-in-
Chief of this journal.
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